Infectious Disease · Medical Literature
[Viewpoint] Hepatitis A prevention in the USA depends on routine universal childhood vaccination
Abstract
On Jan 5, 2026, the Acting Director of the US Centers for Disease Control and Prevention (CDC) signed a decision memorandum from the heads of the National Institutes of Health, the Centers for Medicare & Medicaid Services, and the US Food and Drug Administration, which removed vaccines against meningococcal disease, influenza, COVID-19, hepatitis A, and hepatitis B, including the birth dose, as routinely recommended vaccines for all children.1 Instead, except for certain groups at high risk, these vaccines were recommended for children based on shared clinical decision making.
Clinical relevance
Does removing universal routine childhood hepatitis A vaccination from the U.S. immunization schedule — replacing it with shared clinical decision-making and risk-based recommendations — threaten the public health gains achieved since universal vaccination was adopted in 2006? __SNAPSHOT__ {"studyDesign":"Expert Viewpoint / Policy Commentary (not an original research study; no primary data collected)","setting":"United States; national immunization policy context","sampleSize":"Not applicable (Viewpoint article; no enrolled study population)","population":"U.S. children and the broader population affected by hepatitis A vaccination policy, with particular relevance to underserved communities, people experiencing homelessness, and people who use drugs or alcohol","intervention":"January 5, 2026 CDC decision memorandum reclassifying hepatitis A vaccine from a universally recommended routine childhood vaccine to a shared clinical decision-making / high-risk–only recommendation","comparator":"The prior ACIP standard: universal routine hepatitis A vaccination for all children aged 12–23 months, with catch-up vaccination for children aged 2–18 years (as recommended since 2006 and expanded in 2020)","primaryOutcome":"Anticipated population-level impact on hepatitis A incidence, outbreak risk, population immunity, and health equity if routine universal childhood vaccination is discontinued","followUp":"Not applicable (Viewpoint/policy analysis, not a longitudinal study)","fundingSource":"Not reported; authors affiliated with Cornell University and the Coalition for Global Hepatitis Elimination, Task Force for Global Health, Emory University"}
Key findings
This is an expert Viewpoint, not an interventional or observational study; no original data, p-values, confidence intervals, or effect sizes are generated. The authors — both former architects of CDC hepatitis A vaccination recommendations — argue that universal routine childhood vaccination has been the direct driver of a >95% reduction in U.S. hepatitis A cases since the 2006 ACIP recommendation for all children aged 12–23 months, reducing incidence from high pre-vaccine levels to approximately 0.4 cases per 100,000 population by 2011. When vaccination coverage faltered due to rising homelessness and drug use in unvaccinated adult cohorts, the national incidence rebounded to 5.7 cases per 100,000 by 2019, accompanied by outbreaks across 37 states with approximately 45,000 confirmed cases, approximately 27,000 hospitalizations, and 424 deaths between 2016 and 2023. The authors contend that the January 5, 2026 CDC reclassification — which also removed meningococcal, influenza, COVID-19, and hepatitis B vaccines including the birth dose from universal routine recommendations — was made without new safety or efficacy data, without ACIP public deliberation, and was instead driven by a cross-national comparison of immunization schedules. They provide a point-by-point rebuttal to the stated rationale, noting that pre-licensure placebo-controlled trials were appropriately conducted and demonstrated vaccine safety; decades of post-licensure surveillance and hundreds of millions of doses worldwide corroborate an excellent safety profile; and the low current incidence of hepatitis A in children is itself the product of the vaccination program. The authors further warn that the shift to shared clinical decision-making risks widening disparities in vaccine access and will expand the reservoir of susceptible children and adults, particularly in underserved communities. Of note, the policy changes were challenged in court and temporarily blocked by a preliminary injunction (American Academy of Pediatrics v. Kennedy, U.S. District Court, District of Massachusetts, March 16, 2026). NNT/NNH: not calculable from a Viewpoint.
Practice implications
This Viewpoint establishes a policy argument grounded in historical epidemiological evidence: that routine universal childhood hepatitis A vaccination has been the primary mechanism for achieving and sustaining low hepatitis A incidence in the U.S., and that removal of this recommendation constitutes a significant public health risk. What it does not establish — and cannot, given its design — is a prospective causal estimate of the magnitude of outbreak risk, the timeline to susceptibility accumulation, or the quantified effect of the shared decision-making model on actual vaccination coverage. The findings apply to the full U.S. pediatric population, with greatest relevance for clinicians serving communities with high rates of homelessness, substance use, or historically low vaccination coverage. Populations not well represented by a Viewpoint format include those in whom granular risk-stratification for shared decision-making might be clinically feasible. The clinical importance of the argument is high: the 2016–2023 outbreak data demonstrate that lapsed population immunity translates into measurable morbidity and mortality. Critically, the article is available only as an abstract/viewpoint summary to this reviewer; the full text may contain additional nuance. Clinicians should be aware that professional society recommendations (e.g., AAP 2026 immunization schedule) currently maintain routine hepatitis A vaccination for all children, diverging from the revised federal CDC schedule, and that insurance coverage obligations and the legal status of the federal schedule changes remain in flux. __LIMITATIONS__ 1. Study design: This is an opinion/policy Viewpoint, not a systematic review, meta-analysis, or original epidemiologic study; it presents no new primary data and cannot establish causal projections. 2. Potential author bias: Both authors are former CDC hepatitis A vaccine policy architects with a stated position in favor of restoring universal vaccination; competing perspectives are not formally adjudicated. 3. Epidemiologic inference: The causal attribution of case reductions to vaccination (rather than concurrent behavioral or social changes) is supported by historical MMWR data but not re-examined de novo in this article. 4. Generalizability of international comparisons: The CDC's rationale referenced peer-nation schedules, but the authors note that countries such as Israel, Brazil, and the Republic of Korea maintain universal hepatitis A vaccination; the comparator nations cited by HHS are not formally evaluated in this Viewpoint. 5. Impact of shared decision-making model on coverage rates: No prospective data on the anticipated coverage reduction or outbreak probability under the new framework are provided; projections remain qualitative. 6. Abstract-only access: Full article text was not available for review, limiting assessment of complete methodology, citation quality, and any quantitative modeling performed. 7. Rapidly evolving legal and policy landscape: The preliminary court injunction temporarily blocking these changes means the operational status of the recommendations may differ from the policy as described at the time of publication. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ Routine universal childhood hepatitis A vaccination, in place since 2006, is directly responsible for a greater than 95% reduction in U.S. hepatitis A incidence; the 2016–2023 outbreak experience demonstrates that lapses in population immunity rapidly translate into tens of thousands of cases, hospitalizations, and deaths. The January 2026 reclassification of the hepatitis A vaccine to a shared clinical decision-making recommendation was made without new safety or efficacy evidence and without standard ACIP deliberation. Clinicians should be aware that major professional societies (AAP) continue to recommend routine hepatitis A vaccination for all children aged 12–23 months and that the federal policy change is subject to ongoing legal challenge.